<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002331</url>
  </required_header>
  <id_info>
    <org_study_id>214A</org_study_id>
    <secondary_id>M93-069</secondary_id>
    <nct_id>NCT00002331</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS</brief_title>
  <official_title>A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      PRIMARY: To assess the tolerability of the combination regimen of clarithromycin plus
      ethambutol with or without clofazimine in patients with disseminated Mycobacterium avium
      Complex (dMAC).

      SECONDARY: To determine the proportion of patients achieving a sterile blood culture along
      with the time required to achieve it. To determine the duration of bacteriological response,
      defined as length of time that blood cultures remain sterile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1994</start_date>
  <completion_date type="Actual">March 1995</completion_date>
  <primary_completion_date type="Actual">March 1995</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Mycobacterium Avium-intracellular Infection</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  History of HIV seropositivity.

          -  Disseminated MAC.

          -  Positive blood culture for MAC within 4 weeks prior to study entry.

          -  Consent of parent or guardian if less than 18 years of age.

          -  Ability to complete the study.

        NOTE:

          -  Patients with active opportunistic infections other than dMAC are permitted if dosage
             and clinical parameters have been stable for 4 weeks prior to enrollment.

        Exclusion Criteria

        Concurrent Medication:

        Excluded:

          -  Active therapy with carbamazepine or theophylline, unless investigator agrees to
             carefully monitor blood levels.

          -  Active therapy with investigational drugs other than treatment for HIV disease, except
             with approval of the sponsor.

          -  Concomitant terfenadine (Seldane or Seldane-D) or astemizole (Hismanal).

          -  Amikacin.

          -  Azithromycin.

          -  Capreomycin.

          -  Ciprofloxacin.

          -  Cycloserine.

          -  Ethionamide.

          -  Gentamicin.

          -  Kanamycin.

          -  Levofloxacin.

          -  Lomefloxacin.

          -  Ofloxacin.

          -  Rifampin.

          -  Rifabutin.

          -  Sparfloxacin.

          -  Streptomycin.

          -  Any other aminoglycosides, quinolones, and macrolides.

        Patients with the following prior conditions are excluded:

        History of allergy or hypersensitivity to macrolides, ethambutol, or clofazimine.

        Prior Medication:

        Excluded:

          -  Other antimycobacterials, including aminoglycosides, ansamycin (rifabutin), other
             macrolides (such as clindamycin), quinolones, and rifampin, between screening and
             study entry.

          -  Clarithromycin or azithromycin as prophylaxis or treatment (for any cause) for more
             than 14 days cumulative within the past 2 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaiser Permanente Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCD Med Ctr</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Med Ctr</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>951282699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Margaret Fischel</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hosp / Infectious Disease Rsch Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>701122699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Univ School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Stephen Hauptman</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Southwestern Med Ctr of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Veterans Administration Med Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Javier Morales</name>
      <address>
        <city>Condado San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, Benson CA, Meek K, Siepman N, Craft JC. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS. 1997 Mar;11(3):311-7.</citation>
    <PMID>9147422</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <keyword>Mycobacterium avium-intracellular Infection</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Ethambutol</keyword>
  <keyword>Clofazimine</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Clarithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

